Cannon-Albright has used biomedical informatics to develop the analytical methods for using the unique family-based genetic resource known as the Utah Population Database to look for disease-causing gene mutations in large, multigenerational families. Working with other University of Utah researchers, she has contributed to seminal discoveries of mutations related to hereditary breast cancer, melanoma and colon cancer. Recently, she identified a prostate cancer susceptibility gene. Several of her discoveries have led to patented technologies, some of which have formed the basis for new diagnostic tests. She came to the University in 1988.
Prestwich, who joined the University's College of Pharmacy in 1996, has been a prolific researcher, inventor and entrepreneur for over 30 years. His work first led to chemical tools used for research in lipid signaling and drug discovery in cancer. Additional inventions consist of hyaluronic acid hydrogels that facilitate rapid wound healing and also are used for cell therapy and regenerative medicine. The latest patents support the development of drugs to treat chronic inflammation of the bladder and periodontal tissues. These inventions, and others, comprise more than 27 patents and have led Prestwich to found eight companies, including Echelon Biosciences, Glycosan Biosystems (now BioTime), and GlycoMira Therapeutics.
"One of the better kept secrets in academic medicine is the caliber of innovative researchers and clinicians we have at the University of Utah Health Sciences," says Vivian Lee, MD, PhD, M.B.A., senior vice president for health sciences, dean of the School of Medicine and CEO of University of Utah Health Care. "As academic medical centers, advancing the science and delivery of health care is key to o
|Contact: Phil Sahm|
University of Utah Health Sciences